For research use only. Not for therapeutic Use.
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC)[1].
Girentuximab is an IgG1 κ light chain chimeric version of a murine monoclonal antibody (mAb) and recognizes the antigen CAIX[1].
| Catalog Number | I043775 |
| CAS Number | 916138-87-9 |
| Purity | ≥95% |
| Reference | [1]. Chamie K, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3(7):913-920. |
